Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFlorentin, M.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorTellis, C. C.en
dc.contributor.authorDerdemezis, C. S.en
dc.contributor.authorElisaf, M.en
dc.contributor.authorTselepis, A.en
dc.date.accessioned2015-11-24T16:57:22Z
dc.date.available2015-11-24T16:57:22Z
dc.identifier.issn0003-3197-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10572
dc.rightsDefault Licence-
dc.subjectadiponectinen
dc.subjectezetimibeen
dc.subjectfenofibrateen
dc.subjectleptinen
dc.subjectrimonabanten
dc.subjectvisfatinen
dc.subjectmolecular-weight adiponectinen
dc.subjectcardiometabolic risk-factorsen
dc.subjectmetabolic syndromeen
dc.subjectvisfatin levelsen
dc.subjectinsulin-resistanceen
dc.subjectoverweight/obese patientsen
dc.subjectendocannabinoid systemen
dc.subjectmicronized fenofibrateen
dc.subjectcardiovascular-diseaseen
dc.subjectenergy-balanceen
dc.titleEffects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Studyen
heal.abstractWeight loss and hypolipidemic drugs can improve lipid and adipokine levels. We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia. Overweight/obese patients (n = 60, body mass index = 27-40 kg/m(2)) with mixed dyslipidemia were recruited. Patients received a hypocaloric diet and were randomized to rimonabant 20 mg/d (group R, n = 20), rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20), or rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20). After 3 months, leptin concentration was significantly reduced in all groups (-38%, P < .005; 40%, P < .005; and 44%, P < .001 in the R, RF, and RE groups, respectively). Total adiponectin remained unaltered. Visfatin concentration decreased significantly only in the RE and RF groups (-18% and 38%, respectively; P < .047). Treatment with rimonabant may improve adipokine levels in overweight/obese patients with dyslipidemia. The addition of fenofibrate or ezetimibe may reinforce this effect.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1177/0003319709352488-
heal.identifier.secondary<Go to ISI>://000276897300009-
heal.identifier.secondaryhttp://ang.sagepub.com/content/61/4/365.full.pdf-
heal.journalNameAngiologyen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ